OGT Inks Deal with Institute of Cancer Research to Advance microRNA-Based Prostate Cancer Test. Journal of Clinical Bioinformatics | Abstract | MicroRNAs: an emerging science in cancer epigenetics. Widespread inference of weighted microRNA-mediated gene regulation in cancer transcriptome analysis. Cancer RNAi Therapeutics Moving On. As RNAi Therapeutics targeting genes expressed in the liver, especially for orphan indications, have captured much of the recent interest in the technology, it is time to once again pay closer attention to RNAi Therapeutics in the oncology space.
Atu027 and TKM-PLK1 Moving into Phase II Silence Therapeutics have just announced that they got the green light from the German regulators to test Atu027 in combination with small molecule gemcitabine in pancreatic cancer. Following a short phase Ib to establish the safety of the combination (note: the original phase I was a monotherapy trial), the plan is to rapidly move into phase II which will aim at establishing proof of concept for efficacy.
Depending on the funding situation, it is possible that the company will expand Atu027 into other indications in phase II, possibly in collaboration with private investigators in the UK. The challenge with Atu027, however, is that the gene target, PKN3, remains a relative black box. RNAi Therapeutics. Duke Researchers Find Role for miR-126/miR-126* in Stopping Breast Cancer Metastasis. With Cancer Drug Nearing End of Phase Ib/IIa Trial, Senesco Exploring Partnership Opportunities. Lab21 to Develop microRNA-Based Colorectal Cancer Diagnostic for IntegraGen. Non-coding RNAs: The cancer X factor. A smoking gun in lung cancer epigenetics. EurekAlert! - Science News. Webinar Recording – Analyzing the Cancer Transcriptome – Illuminating the Dysfunctional Cancer Genome. Deep genomic analysis identifies a micro RNA opponent for ovarian cancer.
UT MD Anderson scientists find miR-506 works by blocking epithelial-to-mesenchymal cell transition MD Anderson News Release 02/11/13 Wei Zhang, Ph.D. Researchers employed an extensive analysis of genomic information to identify a new, high-risk cohort of ovarian cancer patients, characterize their tumors, find a potential treatment and test it in mouse models of the disease. The exhaustive analysis that led to micro RNA 506 (miR-506) as a potential therapeutic candidate for advanced or metastatic ovarian cancer is the cover article in the Feb. 11 edition of Cancer Cell.
"Functional analysis showed that miR-506 is a robust inhibitor of a cellular transition that makes ovarian cancer cells more resistant to treatment and likely to spread. Micro RNAs do not code for genes like their cousins, the messenger RNAs. Analysis of human tumors showed higher miR-506 expression is associated with longer overall survival. There are a number of significant differences between the two types of cell.
In Ovarian Cancer MiR-506 Works By Blocking Epithelial-To-Mesenchymal Cell Transition. Nanotech'ed RNA drug reduces ovarian cancer tumors by 83 percent. By loading fragile RNA into silicon nanoparticles, researchers from The Methodist Hospital and two other institutions found a new drug delivery system can reduce the size of ovarian tumors by as much as 83 percent -- and stop tumor growth in chemotherapy-resistant ovarian cancer tissue. The study, conducted in animal models, is published in an upcoming issue of Clinical Cancer Research (now online). "Drug resistance is a huge problem in the clinic," said Mauro Ferrari, Ph.D., one of the senior authors of the paper.
"Our work shows that protecting the RNA longer so that it can get to where it must go and do its work inside cancer cells not only increases the RNA's impact, but also makes drug-resistant cancer cells once again sensitive to commonly used chemotherapy drugs. " The National Cancer Institute estimates that 1 in 72 women born today will be diagnosed with ovarian cancer at some point during their lives. While safe, the siRNA can't simply be injected into a patient. In Ovarian Cancer MiR-506 Works By Blocking Epithelial-To-Mesenchymal Cell Transition. Study Demonstrates Therapeutic Effect of RNAi Gene Silencing in Cancer Treatment.
MiRNAs and Bladder Cancer – Study Validating Ability of microRNAs to Predict Progression. NOTE: hsa-miR-29c* mentioned in the following paper is the retired name for what is now hsa-miR-29c-5p: PHILADELPHIA and REHOVOT, Israel, Feb. 7, 2013 /PRNewswire/ — Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, today announced that data from a study demonstrating the ability of microRNA expression to serve as a biomarker to predict the progression of bladder urothelial carcinoma were published online in the British Journal of Urology International, in an article entitled, “Predicting progression of bladder urothelial carcinoma using microRNA expression.”
The article can be accessed online at and is expected to be published in the print edition of the British Journal of Urology International. Study author Prof. SOURCE Rosetta Genomics Ltd. In Lung Cancer, RNA Promotes Metastasis. The vast majority - approximately 80 percent - of our DNA does not code for proteins, yet it gets transcribed into RNA. These RNA molecules are called non-coding and fulfill multiple tasks in the cell. Alongside a well-studied group of small RNAs, there is also a class of so-called long non-coding RNAs consisting of more than 200 nucleotides. Long non-coding RNAs regulate cellular processes such as cell cycle, growth and cell death. Therefore, it came as no surprise that many of these controlling molecules are linked to the progression of cancer... dna majority progression rna rnas oxo Remove a tag from the tag selection xox Keep a tag in the selection and remove others The vast majority - approximately 80 percent - of our DNA does not code for proteins, yet it gets transcribed into RNA.
Dna influence majority malat rna rnas direction dna institute lncrnas mrna mrnas organization production regulation rna rnas transcription whitehead. Non-coding RNA MALAT1 influences lung cancer metastasis. The vast majority - approximately 80 percent - of our DNA does not code for proteins, yet it gets transcribed into RNA. These RNA molecules are called non-coding and fulfill multiple tasks in the cell. Alongside a well-studied group of small RNAs, there is also a class of so-called long non-coding RNAs consisting of more than 200 nucleotides.
Long non-coding RNAs regulate cellular processes such as cell cycle, growth and cell death. Therefore, it came as no surprise that many of these controlling molecules are linked to the progression of cancer. In his current project, Diederichs has investigated the actual mechanisms used by MALAT1 to interfere in cellular processes and to promote metastasis. For the first time, Diederichs and his team have been able to achieve almost complete silencing of MALAT1 in lung cancer cell cultures. THE MEDICAL NEWS | from News-Medical.Net - Latest Medical News and Research from Around the World. Non-coding RNA MALAT1 influences lung cancer metastasis. The vast majority - approximately 80 percent - of our DNA does not code for proteins, yet it gets transcribed into RNA. These RNA molecules are called non-coding and fulfill multiple tasks in the cell. Alongside a well-studied group of small RNAs, there is also a class of so-called long non-coding RNAs consisting of more than 200 nucleotides. dna influence majority malat rna rnas oxo Remove a tag from the tag selection xox Keep a tag in the selection and remove others The vast majority - approximately 80 percent - of our DNA does not code for proteins, yet it gets transcribed into RNA.
These RNA molecules are called non-coding and fulfill multiple tasks in the cell. Alongside a well-studied group of small RNAs, there is also a class of so-called long non-coding RNAs consisting of more than 200 nucleotides. Dna majority progression rna rnas. Targeting Cancer Metastasis. PhaseRx Inks Tech-Evaluation Deal with Monsanto as It Advances Liver Cancer Program. RNA fragments may yield rapid, accurate cancer diagnosis. Purestock/Thinkstock Strands of genetic information preserved inside microvesicles, called exosomes, may help scientists diagnose certain forms of cancer and monitor tumor progression.
An article by Scientific American. Fragments of RNA that cells eject in fatty droplets may point the way to a new era of cancer diagnosis, potentially eliminating the need for invasive tests in certain cases. Cancer tumor cells shed microvesicles containing proteins and RNA fragments, called exosomes, into cerebral spinal fluid, blood, and urine. Within these exosomes is genetic information that can be analyzed to determine the cancer’s molecular composition and state of progression. Researchers at Massachusetts General Hospital discovered that exosomes preserve the genetic information of their parent cells in 2008, however exosomes have not seen widespread clinical testing as a means of cancer diagnosis until now. From a technical standpoint I don’t believe there is a barrier,” Carter says.
RNA fragments may yield rapid, accurate cancer diagnosis. First-in-Man Trial of an RNA Interference Therapeutic Targeting VEGF and KSP in Cancer Patients with Liver Involvement. + Author Affiliations ↵* Corresponding Author: Josep Tabernero, Medical Oncology, Vall d'Hebron University Hospital, P. Vall d'Hebron 119-129, Barcelona, 08035, Spain jtabernero@vhebron.net RNAi is a potent and specific mechanism for regulating gene expression. Harnessing RNAi to silence genes involved in disease holds promise for the development of a new class of therapeutics. Delivery is key to realizing the potential of RNAi, and lipid nanoparticles (LNPs) have proven effective in delivery of siRNAs to liver and tumors in animals. To examine the activity and safety of LNP-formulated siRNAs in man, we initiated a trial of ALN-VSP, an LNP formulation of siRNAs targeting VEGF and KSP, in cancer patients.
Received September 24, 2012. Beijing Institute of Biotechnology Team Links miR-148a to HBV-Associated Cancer. Genomics and epigenomics of colorectal cancer - Schweiger - 2013 - Wiley Interdisciplinary Reviews: Systems Biology and Medicine. Modulation of Cancer Traits by Tumor Suppressor microRNAs. Open AccessThis article isfreely availablere-usable Review Laboratory of Genetics, National Institute on Aging-Intramural Research Program, National Institutes of Health, 251 Bayview Blvd, Baltimore, MD 21224, USA * Author to whom correspondence should be addressed. Received: 20 November 2012; in revised form: 28 December 2012 / Accepted: 10 January 2013 / Published: 16 January 2013 Abstract: MicroRNAs (miRNAs) are potent post-transcriptional regulators of gene expression. Keywords: post-transcriptional gene regulation; oncomiR; tumor suppressor microRNA; senescence; carcinogenesis MDPI and ACS Style Grammatikakis, I.; Gorospe, M.; Abdelmohsen, K.
AMA Style Grammatikakis I, Gorospe M, Abdelmohsen K. Chicago/Turabian Style Grammatikakis, Ioannis; Gorospe, Myriam; Abdelmohsen, Kotb. 2013. Study of the UTMD-Based Delivery System to Induce Cervical Cancer Cell Apoptosis and Inhibit Proliferation with shRNA targeting Survivin. Open AccessThis article isfreely availablere-usable Article 1 Department of Medical Ultrasound, Key Laboratory for Major Obstetric Diseases of Guangdong Province, the Third Affiliated Hospital of Guangzhou Medical University, Guangzhou 510150, China 2 Guangzhou Research Institute of Obstetrics and Gynecology, Key Laboratory for Major Obstetric Diseases of Guangdong Province, the Third Affiliated Hospital of Guangzhou Medical University, Institute of Obstetrics and Gynecology, Guangzhou 510150, China * Author to whom correspondence should be addressed.
Received: 3 November 2012; in revised form: 4 January 2013 / Accepted: 6 January 2013 / Published: 16 January 2013 Abstract: Apoptosis induction by short hairpin RNA (shRNA) expression vectors could be an efficient and promising strategy for cancer gene therapy. Ultrasound-targeted microbubble destruction (UTMD) is an appealing technique. Keywords: ultrasound; microbubble; apoptosis; gene therapy; RNA interference; non-viral vector Chen, Z. Rosetta Genomics Reports Study Comparing microRNA Profiles of Cancer of Unknown Primary and Metastases of Known Primary Tumors. PHILADELPHIA and REHOVOT, Israel, Jan. 9, 2013 /PRNewswire/ — Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, today announced that data from a study assessing the differences between cancer of unknown primary (CUP) and metastatic solid tumors of known primary metastases (KPM) by profiling microRNA expression were recently published in Clinical Experimental Metastasis, in an article entitled “Global microRNA profiling in favorable prognosis subgroups of cancer of unknown primary (CUP) demonstrates no significant expression differences with metastases of matched known primary tumors.”
The article can be viewed online at The study assessed microRNA differences between CUP metastases with favorable prognosis and metastases of known primary tumors in order to screen for an aggressive, pro-metastatic, CUP-specific biologic signature. The study consisted of two stages. Znfx1as_diagnostic_180811.pdf?utm_source=dlvr. Kyowa Selects Second Cancer Drug Candidate under Dicerna Partnership. TNF-α Gene Knockout in Triple Negative Breast Cancer Cell Line Induces Apoptosis. Open AccessThis article isfreely availablere-usable Article 1 Faculty of Pharmacy, "Iuliu Hatieganu" University of Medicine and Pharmacy, 4 Pasteur Street, Cluj-Napoca 400349, Romania 2 Department of Functional Genomics and Experimental Pathology, Cancer Institute "Ioan Chiricută", 34–36 Republici Street, Cluj-Napoca 400015, Romania 3 Research Center for Functional Genomics, Biomedicine and Translational Medicine, "Iuliu Hatieganu" University of Medicine and Pharmacy, 8 Victor Babes Street, Cluj-Napoca 400012, Romania 4 Surgical Clinic II, 4–6 Clinicilor Street, Cluj-Napoca 400006, Romania 5 Department of Surgery, "Iuliu Haţieganu" University of Medicine and Pharmacy, 8 Victor Babes Street, Cluj-Napoca 400012, Romania * Author to whom correspondence should be addressed.
Received: 9 October 2012; in revised form: 30 November 2012 / Accepted: 6 December 2012 / Published: 24 December 2012 Keywords: RNA interference; apoptosis; cell signaling pathways; gene therapy MDPI and ACS Style AMA Style. A Trio Of MicroRNAs Contributes To Liver Cancer Progression. New Molecule Linked To Late-Stage Breast Cancer Discovered. Researchers at Case Western Reserve University School of Medicine have identified a molecule linked to more aggressive forms of breast cancer - a discovery that could point the way to potential cures. Until this study, the ribonucleic acid (RNA) molecule called miR-181a had never before been tied to breast cancer metastasis. But when scientists found elevated levels of the molecule in late-stage breast cancer tissues, they in turn tested an inhibitor in mouse models.
The approach not only prevented metastasis, but also extended the animals' lives... medicine reserve rna school scientists university western oxo Remove a tag from the tag selection xox Keep a tag in the selection and remove others A research team from Case Western Reserve University School of Medicine has discovered an approach that could make gene therapy dramatically more effective for patients. A team of researchers led by Dr. Infection medicine reserve school university western yale. BMC Cancer | Abstract | Overexpression of SERBP1 (Plasminogen activator inhibitor 1 RNA binding protein) in human breast cancer is correlated with favourable prognosis. Opportunities and methods for studying alternative splicing in cancer with RNA-Seq. MED12 Controls the Response to Multiple Cancer Drugs through Regulation of TGF-β Receptor Signaling. Accelerating cancer systems biology research through Semantic Web technology - Wang - 2012 - Wiley Interdisciplinary Reviews: Systems Biology and Medicine.
Debiopharm Drops Out of Bladder Cancer Deal with Cash-Strapped Marina | Gene Silencing News. Shah Lab for Computational Cancer Biology | deFuse: gene fusion discovery using RNA-Seq. DeFuse is a software package for gene fusion discovery using RNA-Seq data. The software uses clusters of discordant paired end alignments to inform a split read alignment analysis for finding fusion boundaries.
A classifier trained on real fusions and false positives is applied to the assembled sequences. The software produces a fully annotated output for each predicted fusion. The software is designed to be run out of the box with little configuration, and is compatible SGE, PBS and LSF compute clusters. deFuse has been used to discover gene fusions in tumour samples for the following papers:MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers, Nature 2011 The deFuse algorithm and results from an application to ovarian tumours and sarcomas was published in PLoS Computational Biology:deFuse: An Algorithm for Gene Fusion Discovery in Tumor RNA-Seq Data Download: Request for Software Download here See the defuse sourceforge project page for more information.
Microfluidic Chip Offers Fast RNA Detection From Ultra-Small Sample, Has Implications For Cancer And Alzheimer's Diagnosis. BMC Cancer | Abstract | PCA3 noncoding RNA is involved in the control of prostate-cancer cell survival and modulates androgen receptor signaling. Sign In. Sign In. BMC Cell Biology | Abstract | Phosphorylation of P68 RNA Helicase by P38 MAP kinase contributes to colon cancer cells apoptosis induced by oxaliplatin.
Identification of novel transcripts deregulated in bucc... [Gene. 2012. Cancer_bio : Mirna Therapeutics Secures... Long non-coding RNAs in cancer progression. RNA biomarkers in colorectal cancer. [Methods. 2012. The Role of MicroRNAs in Breast Cancer Migration, Invasion and Metastasis. Cancer_bio : Articles A wholeblood RNA... MicroRNA: a bridge from H. pylori infection to gastritis and gastric cancer development. A Multiplex Assay to Measure RNA Transcripts of Prostate Cancer in Urine. PIWI expression and function in cancer. Recurrent R-spondin fusions in colon cancer : Nature. Unraveling 50-year-old clues linking neurodegeneration and cancer to cycad toxins: are microRNAs a common mediator?
PDX-1 Is a Therapeutic Target for Pancreatic Cancer, Insulinoma and Islet Neoplasia Using a Novel RNA Interference Platform. Delivery of chemo-sensitizing siRNAs to HER2+-breast cancer cells using RNA aptamers. Whole Transcriptome RNA-Seq Analysis of Breast Cancer Recurrence Risk Using Formalin-Fixed Paraffin-Embedded Tumor Tissue. Cancer Epigenetics: From Mechanism to Therapy. Cancer_bio : RNA sequencing of pancreat... Sequence analysis of mutations and translocations across breast cancer subtypes : Nature. The polymorphism rs944289 predisposes to papillary thyroid carcinoma through a large intergenic noncoding RNA gene of tumor suppressor type. Lipid-Based Nanoparticles for siRNA Delivery in Cancer Therapy: Paradigms and Challenges - Accounts of Chemical Research.
Cancer.